COMPANY:

BostonGene

"BostonGene...today announced that four abstracts have been accepted for presentation at the Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo, taking place November 19 - 23 at the Vancouver Convention Centre in Vancouver, British Columbia, Canada."

"BostonGene...announced the Company will present six posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting taking place November 6-10, 2024 at the George R. Brown Convention Center in Houston, Texas. The research, conducted in collaboration with leading cancer centers, showcases the impact of BostonGene’s technology in advancing cancer treatment strategies, from deep molecular insights to predictive biomarkers."

"Fujita Health University and BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, announced today that the Fujita Health University Haneda Clinic will now offer genomic profile testing for cancer patients utilizing the BostonGene Tumor Portrait test."

"BostonGene...announced its participation in the 14th Annual Association for Value-Based Cancer Care (AVBCC) Summit and Educational Program. The summit, scheduled for October 16 - 18 in New York City, will bring together oncology professionals, payers, and industry leaders to explore the implementation of value-based models aimed at enhancing the quality and cost effectiveness of cancer care."

"BostonGene...and Sarah Cannon Research Institute (SCRI)...announced a collaboration aimed at integrating innovative molecular testing and informatics platforms into clinical decision-making processes at SCRI phase 1 clinics. Additionally, the collaboration seeks to validate novel biomarkers using BostonGene’s AI-powered multiomics platform in real-world cancer populations...This collaboration will establish robust data connectivity between BostonGene and SCRI’s precision medicine platform Genospace. By integrating BostonGene’s advanced testing platform into clinical workflows at community oncology clinics, the effects of molecular profiling on clinical trial enrollment frequency will be examined, including the impact of human leukocyte antigens (HLA) genotyping on pre-screening patients....BostonGene will provide its CLIA-certified, CAP-accredited Tumor Portrait tests to clinicians at SCRI’s phase 1 sites."

"BostonGene...and researchers from multiple cancer centers including, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Weill Cornell Medicine and Washington University School of Medicine in St. Louis and others...announced the online publication of the manuscript 'Deep Clinical Responses and Limited Inflammatory Toxicity in Patients with Relapsed/Refractory T-cell Lymphomas Receiving Duvelisib and Romidepsin' in Nature Medicine."

"Presentations highlight BostonGene's comprehensive profiling, revealing potential biomarkers and therapeutic targets that expand treatment options and advance support for biomarker-driven clinical trials."

"BostonGene...announced they will collaborate with the Icahn School of Medicine at Mount Sinai on a precision medicine clinical study in multiple myeloma (MM). The study aims to evaluate and improve cancer sequencing for the characterization of tumor molecular vulnerabilities and the identification of novel therapeutics, paving the way for developing targeted therapies and personalized treatment approaches for MM patients."

"BostonGene...announced its participation in the 14th World Clinical Biomarkers & CDx Summit 2024, taking place September 3 - 6 in Boston, Massachusetts. The event will bring together drug developers, diagnostics providers, and payers to advance biomarker-driven clinical trials, focusing on early biomarker discovery, clinical strategy optimization and the commercialization of precision therapies."

"BostonGene...announced that two abstracts have been accepted for the 22nd Annual Meeting of the Japanese Society of Digital Pathology in 2024, scheduled to take place August 29 - 31, 2024, at Meio University in Nago, Japan."

"BostonGene...announced that it will collaborate with Takeda on immuno-oncology focused research studies. This partnership aims to identify key molecular drivers and predictive markers for treatment efficacy and adverse effects with the primary goal of advancing clinical solutions and improving patient outcomes....Takeda will leverage BostonGene's AI-powered multiomics platform in select early-stage clinical trials to enhance trial design, improve indication selection and identify biomarker signatures for response and toxicity. BostonGene will perform sophisticated multiomic analytics using proprietary computational platforms on clinical and laboratory data provided by Takeda. Additionally, BostonGene will conduct extensive bioinformatics analysis on flow cytometry, RNA-seq and proteomics data."

"BostonGene...and Sylvester Comprehensive Cancer Center...today announced a master agreement to propel collaborative research between the two organizations. Leveraging BostonGene's expertise in AI-powered molecular and immune profiling solutions and Sylvester’s extensive research capabilities, the collaboration will focus on validating blood- and bone marrow-based assays for hematological cancers....'The collaboration between BostonGene and Sylvester Comprehensive Cancer Center holds immense promise for advancing cancer care, particularly for hematological cancer patients. By combining next-generation sequencing (NGS)-based tumor profiling with traditional diagnostic methods like fluorescence in situ hybridization (FISH) and cytogenetics, we aim to improve the accuracy of molecular subtyping, which is vital for personalized treatments,'..."

"BostonGene...announced that it will participate in the hubXchange’s Immuno-Oncology Xchange - Boston 2024, taking place June 18 in Boston, Massachusetts. The event brings together executives from pharma and biotech to address and find solutions to the key issues that are currently faced in Immuno-Oncology."

P1b | N=9 | NCT03267836 | "BostonGene...announced that seven abstracts have been accepted for the 2024 ASCO Annual Meeting (ASCO), scheduled to take place May 31 – June 3, 2024, at McCormick Place Convention Center in Chicago, IL. BostonGene will deliver one oral presentation and present two posters, while four abstract presentations will be available online. BostonGene will also exhibit at booth 22157....The use of RNA-seq and MxIF on pre- and post-avelumab tumor tissues revealed that for some patients the combination (avelumab + RT) may cause an immunological response leading to prolonged remission, warranting further larger prospective studies and biomarker investigations."

"BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced the publication, “Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancer” in Cancer Cell, the premier scientific journal to publish articles with significant advances in cancer research and oncology. This study describes the development of a platform for patient immune system profiling, establishing a novel classification and scoring system that correlates systemic immunity with patient responses to various cancer treatments, highlighting a new discovery for drug development and clinical care."

"BostonGene...announced the manuscript 'Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for PDAC' has published online and in print in Gastroenterology, the premier journal in the field of gastrointestinal disease...The journal highlights original research, reviews and expert insights in adult and pediatric gastroenterology and hepatology, covering clinical, translational and basic aspects of the digestive system, liver, pancreas and nutrition. The study identified four distinct tumor microenvironment (TME) subtypes, unveiling a promising path forward in the fight against PDAC and underscoring the importance of considering TME features in personalized therapeutic strategies."

"BostonGene...and the Parker Institute for Cancer Immunotherapy (PICI)...announced today the launch of a collaboration aimed at uncovering molecular mechanisms underlying IO treatment response and treatment-related toxicity in advanced cancer patients and discovering actionable blood-based biomarkers. BostonGene will analyze longitudinal blood samples from PICI’s RADIOHEAD (Resistance Drivers for Immuno-Oncology Patients Interrogated by Harmonized Molecular Datasets) program, a prospective study of approximately 1,200 pan-cancer patients on standard of care immune checkpoint inhibitor treatment regimens....PICI’s mission-focused collaboration with BostonGene is a significant step toward unlocking the potential of blood-based biomarkers to advance personalized immunotherapy."

"BostonGene...announced today the launch of a collaboration aimed at discovering biomarkers for immunotherapy (IO) treatment response and treatment-related toxicity in advanced non-small cell lung cancer (NSCLC) patients....This study will evaluate the tumor microenvironment (TME) utilizing the BostonGene Tumor Portrait test in tissue samples collected before EGFR-TKI treatment and before ICI administration in patients with EGFR-positive lung adenocarcinoma."

"BostonGene...announced that eight abstracts were selected for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024, which will be held from April 5 - 10, at the San Diego Convention Center in San Diego, CA. BostonGene will exhibit at booth #847....This study shows the feasibility and utility of comprehensive molecular profiling to match patients to WES-informed treatments within a clinically relevant time frame. The high rate of additional actionable findings identified by BostonGene’s analytical platform suggest comprehensive testing may offer benefit over traditional targeted panels in solid tumor patients."

"BostonGene...today announced its participation in the Molecular Analysis for Combination Therapy Choice (ComboMATCH) precision medicine initiative as a designated laboratory. ComboMATCH is a follow-up to the largest precision medicine clinical trial, the National Cancer Institute (NCI)-MATCH trial. ComboMATCH aims to overcome drug resistance to single-drug therapies by developing targeted drug combinations. NCI is a part of the National Institutes of Health....A unique initiative to test new combinations of cancer drugs guided by tumor biology, ComboMATCH aims to pair patients with locally advanced or advanced solid tumors with a therapy that has the potential to manage their cancer. The study will also assist physicians in devising more effective treatment strategies."

"BostonGene...announced it will participate in the United States and Canadian Academy of Pathology (USCAP) 113th Annual Meeting...BostonGene to showcase the power of next-generation multi-platform AI-driven analytics, paving the way for novel cancer therapeutics and showcasing RNA sequencing's crucial role in validating biomarkers assessed pathologically..."

"BostonGene...today announced the publication of the manuscript....The research's key findings included identifying unique histological patterns such as stromal desmoplasia and follicular growth pattern alterations observed before first progression and relapse in FL patients. Additional results provide a comprehensive characterization of the genomic and transcriptomic landscapes of tumor B cells, uncovering diverse genetic lesions and alterations in pathways associated with immune escape, apoptosis resistance, and extracellular matrix remodeling. Utilizing single-cell resolution profiling, the research revealed distinct populations of B cells, T cells, myeloid cells, and stromal cells within FL lymph nodes, shedding light on their spatial distribution within the tumor microenvironment."

"Transgene..., NEC Corporation...and BostonGene Corporation...announced the expansion of their collaboration for the randomized Phase I/II trial of TG4050, an individualized therapeutic vaccine for patients with head and neck cancers. BostonGene is partnering with NEC and Transgene to continue performing tumor molecular profiling and microenvironment analysis and provide high-throughput sequencing services. The partnership with BostonGene will enable fast turnaround of next-generation sequencing (NGS) data, and sophisticated analytics will enable comprehensive profiling of patient immune contexture."

"BostonGene...announced today that it will participate in the 21st Japanese Society of Medical Oncology (JSMO) Annual Meeting. The research conference will be held at the Nagoya Congress Center from February 22 to 24, bringing together a diverse tumor-agnostic academic society focused on pharmacologic therapy with the objective of delivering research to enhance the quality of life for all cancer patients....BostonGene will deliver presentations demonstrating the utility of integrated genomic and transcriptomic profiling in identifying clinically relevant alterations for treatment decision-making and describe the development of AI-based analytical tools and pipelines to comprehensively understand each patient’s disease."

P1 | N=62 | NCT03152318 | "BostonGene...today announced the online publication...in Nature...Utilization of immunotherapy for GBM has been challenging due to the scarcity of infiltrating antitumor lymphocytes caused by a highly immunosuppressive or 'lymphocyte-depleted' tumor microenvironment (TME)....The results demonstrated a single injection of CAN-3110 activated an antitumor immune response in GBM, inducing defined changes in T cell repertoires and tumor transcriptomic signatures. These findings are evidence that intralesional onolytic viruses can convert the immunosuppressive GBM TME to an immunoactivated state that is more responsive to immunotherapy."

"BostonGene...announced...that it will participate in and present at the SLAS2024 International Conference and Exhibition on February 3 – 7, 2024, in Boston, MA at the Boston Convention & Expo Center. This global event brings together a diverse community of scientists from academia, government and industry who are collectively focused on leveraging the power of technology to transform research."

"BostonGene...announced a master agreement with Duke University School of Medicine...to collaborate on multiple research projects across lung cancer, gastrointestinal, genitourinary and skin cancers. The strategic partnership allows Duke physicians and researchers to leverage BostonGene's expertise to drive the molecular and cellular characterization of the patient's tumor, microenvironment and immune system and test its predictive value in response to treatment. For cancer patients undergoing treatment at Duke University, including those participating in clinical trials, BostonGene will provide state-of-the-art analytics, interpretation and visualization of big data obtained from analysis of patients’ genomic, transcriptomic, cell phenotyping, proteomic and imaging studies."

"BostonGene...today announces a collaboration with Prisma Health aimed at advancing the understanding of rare tumors by characterizing the tumor microenvironment (TME), mutational landscape and host immune profiles of patients treated with immune checkpoint inhibitors....In collaboration with Prisma Health’s Rare Tumor Center, BostonGene will analyze tissue and peripheral blood from rare cancer solid-tumor patients to understand the molecular underpinnings of immune-activating drugs commonly used to enhance a person's innate mechanisms to fight cancer. BostonGene will perform detailed analyses of primary tumors and immunoprofiling of matched peripheral blood collected during this cohort of the trial, which is currently enrolling patients."

"BostonGene...announced the online publication of the manuscript, 'Spatial Mapping of Human Hematopoiesis at Single Cell Resolution Reveals Aging-Associated Topographic Remodeling,' in Blood, the most cited peer-reviewed publication in the field of hematology."

"BostonGene...and the Sarcoma Oncology Center, announced a collaboration to expedite the availability of DeltaRex-G. This groundbreaking platform therapy, authorized by the FDA's Center for Biologics Evaluation and Research (CBER), holds immense promise for patients battling advanced pancreatic cancer, osteosarcoma, soft tissue sarcoma, and breast cancer. The designation of DeltaRex-G, a CCNG1 inhibitor, as a platform therapy with the potential to incorporate other FDA-approved drugs, was enabled by BostonGene's pivotal identification of elevated CCNG1 levels in these different cancer types."

"BostonGene...announced the selection of four abstracts for oral presentation, four abstracts as poster presentations, and two abstracts for online publication at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023, in San Diego, California and virtually....This presentation highlights results from the Phase 2 ELARA trial that show efficacy, safety, pharmacokinetic, and exploratory biomarker analyses in relapsed/refractory follicular lymphoma patients treated with tisagenlecleucel after a median follow-up of more than 3 years."

"BostonGene...today announced that two abstracts have been accepted for poster presentations for the 2023 San Antonio Breast Cancer Symposium (SABCS), which will be held December 5 - 9, 2023, at the Henry B. Gonzalez Convention Center in San Antonio, Texas. BostonGene will also exhibit at booth 1515."

"BostonGene...announced that an abstract has been accepted as a poster presentation for the Association for Molecular Pathology (AMP) 2023 Annual Meeting & Expo, which will be held November 14 – 18, 2023, at the Salt Palace Convention Center in Salt Lake City, UT."

"BostonGene...announced that three research studies done in collaboration with Weill Cornell Medicine will be presented as poster presentations at the 20th International Cancer Genome Consortium (ICGC) Scientific Workshop/ 7th Accelerating Research in Genomic Oncology (ARGO) meeting."

"BostonGene...announced a collaboration to support the Phase I/II study of LCB84, a TROP2-directed ADC, in patients with advanced cancers. This first-in-human study is being conducted at leading cancer institutions in the US and Canada to evaluate the safety and preliminary efficacy of LCB84, both as a single-agent therapy and in combination with an immune checkpoint inhibitor (anti-PD-1 antibody)....BostonGene will serve as the study’s central laboratory and analytic partner for exploratory biomarkers, performing in-depth, multi-omic profiling of patients’ tumor tissue and blood samples, including whole-exome sequencing (WES), whole-transcriptome sequencing (RNAseq) of tumor tissue from matched tumor biopsies on the study, and immunoprofiling to identify hundreds of different cell types from a single blood sample."

"BostonGene...announced the Company will present four posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting taking place November 3-5, 2023 at the San Diego Convention Center in San Diego, CA....This study showed that the IHC results of five promising ADC targets (HER3, HER2, TROP2, Nectin4, and aFLR) correlated with their RNA sequencing (RNA-seq) gene expression values, highlighting the potential use of RNA-seq to detect ADC targets....Transcriptomic analysis of human papillomavirus (HPV)+ head and neck squamous cell carcinomas (HNSCCs) revealed a disparity in underlying mechanisms of ICI response, particularly related to the tumor microenvironment (TME), between HPV- and HPV+ HNSCC patients....The results showed that the TME subtypes and CD8+ T cell infiltration were associated with overall and progression-free survival, indicating their potential as predictive biomarkers for immunotherapy response."

"BostonGene...announced its abstract has been accepted for poster presentation at the 2023 CTOS Annual Meeting being held November 1-4, 2023, in Dublin, Ireland."

"BostonGene...and FibroFighters...have announced a collaboration to advance clinical care for FLC patients. FLC is a rare form of liver cancer typically diagnosed in adolescents and young adults under 40. FibroFighters has partnered with BostonGene to leverage their AI and molecular profiling techniques to gain deeper insights and identify targeted treatments. The partnership focuses on strategies to drive patient-centric engagement. FibroFighters will actively promote access to the BostonGene Tumor Portrait test, a revolutionary diagnostic test that unveils critical information about each tumor, including immune microenvironment properties, actionable mutations, biomarkers for therapy response, and recommended treatment strategies."

"BostonGene...announced the BostonGene and Exigent Genomic INsight (BEGIN) Study, designed to demonstrate the clinical benefits of using BostonGene Tumor Portrait^™ test for advanced cancer patients in a community setting. The BEGIN Study will validate improved patient outcomes by tailoring treatments based on combined WES and RNA-seq coupled with AI-powered analytics....As part of the BEGIN study, BostonGene will perform comprehensive analysis using the BostonGene Tumor Portrait^TM test, including DNA whole exome (WES) and RNA transcriptome (RNAseq) sequencing, on patient tumor samples from participating Exigent sites. The study aims to determine the utility and frequency of actionable findings identified by a comprehensive sequencing approach in advanced cancer patients in a real-world setting. The trial will also assess the impact of the BostonGene Tumor Portrait^TM test findings on treatment decisions..."

"BostonGene, a leading provider of AI-based molecular and immune profiling solutions, announced today that it will present three abstracts at ESMO Congress 2023....The event will be held on October 20 - 24, 2023, in Madrid, Spain, at the IFEMA MADRID. BostonGene will also exhibit in Hall 5, booth 550."

"BostonGene...announced...that it will participate in and present at the Festival of Genomics & Biodata...In this session, BostonGene will discuss how advances in next-generation sequencing have generated a wealth of unmined genomic data across myriad fields, including oncology."

"BostonGene...today announced a master agreement with Johns Hopkins University School of Medicine (JHUSOM) to collaborate on multiple clinical research projects. The agreement allows BostonGene and JHUSOM to further identify and validate novel precision medicine approaches....JHUSOM will work with BostonGene on the molecular characterization study of the patient's tumor, microenvironment and immune system and its predictive value in response to treatment. BostonGene’s solution will provide JHUSOM with detailed analysis, interpretation and visualization of big data obtained from cancer patient’s genomic, transcriptomic, proteomic and imaging studies."